DrugId:  1
1. Name:  Tamoxifen
2. Groups:  Approved
3. Description:  One of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.
4. Indication:  Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. 
DrugId:  2
1. Name:  Entolimod
2. Groups:  Investigational
3. Description:  Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.
4. Indication:  Not Available
DrugId:  3
1. Name:  Platinum
2. Groups:  Investigational
3. Description:  Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
4. Indication:  Not Available
DrugId:  4
1. Name:  Naptumomab Estafenatox
2. Groups:  Investigational
3. Description:  Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
4. Indication:  Not Available
DrugId:  5
1. Name:  PCI-27483
2. Groups:  Investigational
3. Description:  PCI-27483 has been used in trials studying the treatment of Pancreatic Cancer, Ductal Adrenocarcinoma, and Exocrine Pancreatic Cancer.
4. Indication:  Not Available
DrugId:  6
1. Name:  Lapachone
2. Groups:  Investigational
3. Description:  Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
4. Indication:  Not Available
DrugId:  7
1. Name:  EHC18
2. Groups:  Investigational
3. Description:  EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
4. Indication:  Investigated for use/treatment in hepatitis (viral, C) and hepatocellular carcinoma.
DrugId:  8
1. Name:  Volociximab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DrugId:  9
1. Name:  Lobaplatin
2. Groups:  Investigational
3. Description:  Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
4. Indication:  Not Available
DrugId:  10
1. Name:  Biomed 101
2. Groups:  Investigational
3. Description:  Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma.
DrugId:  11
1. Name:  Bacillus calmette-guerin substrain connaught live antigen
2. Groups:  Approved, Investigational
3. Description:  Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
4. Indication:  Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). 
DrugId:  12
1. Name:  Endostar
2. Groups:  Investigational
3. Description:  Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  13
1. Name:  Indusatumab vedotin
2. Groups:  Investigational
3. Description:  Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
4. Indication:  Not Available
DrugId:  14
1. Name:  Monalizumab
2. Groups:  Investigational
3. Description:  Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
4. Indication:  Not Available
DrugId:  15
1. Name:  Dusigitumab
2. Groups:  Investigational
3. Description:  Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
4. Indication:  Not Available
DrugId:  16
1. Name:  VPM4001
2. Groups:  Investigational
3. Description:  VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
4. Indication:  Investigated for use/treatment in prostate cancer.
DrugId:  17
1. Name:  Lorvotuzumab mertansine
2. Groups:  Investigational
3. Description:  Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
4. Indication:  Not Available
DrugId:  18
1. Name:  Ascrinvacumab
2. Groups:  Investigational
3. Description:  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
4. Indication:  Not Available
DrugId:  19
1. Name:  Tecemotide
2. Groups:  Investigational
3. Description:  Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
4. Indication:  Not Available
DrugId:  20
1. Name:  Brontictuzumab
2. Groups:  Investigational
3. Description:  Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
4. Indication:  Not Available
DrugId:  21
1. Name:  ABT-869
2. Groups:  Investigational
3. Description:  ABT-869 is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. ABT-869 is intended for the treatment of hematologic malignancies and the solid tumors.
4. Indication:  Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
DrugId:  22
1. Name:  Tremelimumab
2. Groups:  Investigational
3. Description:  Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
4. Indication:  Not Available
DrugId:  23
1. Name:  Trebananib
2. Groups:  Investigational
3. Description:  Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  Emibetuzumab
2. Groups:  Investigational
3. Description:  Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  25
1. Name:  WX-G250
2. Groups:  Investigational
3. Description:  WX-G250 is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC). 
4. Indication:  Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.
